65
Participants
Start Date
August 25, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2029
This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65
The RSV vaccine (Arexvy) has demonstrated efficacy against LRTD over three RSV seasons in individuals aged 60 and older, with an acceptable safety and reactogenicity profile. However, data on vaccine responses in individuals aged 80 and older, including frail individuals, remains limited. This population is particularly affected by severe RSV infections, highlighting the need for further investigation to address these gaps.
RECRUITING
Familjeläkarna SÄBO, Saltsjöbaden
RECRUITING
Akademiskt specialistcentrum Studieenheten, Stockholm
Karolinska Institutet
OTHER
Karin Karin Loré
OTHER